Skip to content

Haemonetics HAE Compensation and benefits

Compensation and benefits at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$1.35B+8.0%
Abbott logo
AbbottABT
TFX
TeleflexTFX
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Solventum logo
SolventumSOLV

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's compensation and benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's compensation and benefits?
Haemonetics (HAE) reported compensation and benefits of $68.19M in Q1 2026.
How has Haemonetics's compensation and benefits changed year-over-year?
Haemonetics's compensation and benefits increased by 14.8% year-over-year, from $59.42M to $68.19M.
What is the long-term trend for Haemonetics's compensation and benefits?
Over 5 years (2021 to 2026), Haemonetics's compensation and benefits has grown at a 7.5% compound annual growth rate (CAGR), from $47.6M to $68.19M.